Allarity Therapeutics Files Registration Statement for Proposed $100 Million SPAC IPO

On September 11, 2026, Allarity Therapeutics (NASDAQ:
ALLR) announced that its newly formed SPAC, Allarity Acquisition Corp., publicly filed a Form S-1 registration statement with the SEC for a proposed initial public offering.

The proposed SPAC IPO is expected to raise $100 million, or up to $115 million if underwriters fully exercise their over-allotment option.

Allarity’s wholly owned subsidiary, ALLR Sponsor LLC, is expected to sponsor the SPAC and own approximately 25% of its outstanding shares after the offering, subject to the offering terms.

Maxim Group LLC is serving as the sole book-running manager.

The filing is preliminary and has not yet become effective. The announcement does not mean that the IPO or any subsequent business combination has been completed.

Allarity says the strategic capital allocation is intended to support the SPAC structure while it continues developing stenoparib, its Phase 2 dual PARP/Wnt pathway inhibitor, and its DRP technology.